These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27390581)

  • 41. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transrectal real-time elastography-guided transperineal prostate biopsy as an improved tool for prostate cancer diagnosis.
    Wang R; Chen JJ; Hu B
    Int J Clin Exp Med; 2015; 8(4):6522-9. PubMed ID: 26131282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection rate for significant cancer at confirmatory biopsy in men enrolled in Active Surveillance protocol: 20 cores vs 30 cores vs MRI/TRUS fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Barbera M; Panella P; Pennisi M; Morgia G
    Arch Ital Urol Androl; 2016 Dec; 88(4):300-303. PubMed ID: 28073197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low-risk prostate cancer.
    Porcaro AB; Inverardi D; Corsi P; Sebben M; Cacciamani G; Tafuri A; Processali T; Pirozzi M; Mattevi D; De Marchi D; Amigoni N; Rizzetto R; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Minerva Urol Nefrol; 2020 Feb; 72(1):66-71. PubMed ID: 30298710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy.
    Moreira DM; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):106-112. PubMed ID: 29203895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
    Pepe P; Garufi A; Priolo G; Pennisi M
    World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low risk patients benefit from extreme anterior apical sampling on initial biopsy for prostate cancer diagnosis.
    Elshafei A; Kartha G; Li Y; S Moussa A; Hatem A; Gao T; Jones JS
    Prostate; 2014 Sep; 74(12):1183-8. PubMed ID: 24962004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
    Ochiai A; Troncoso P; Chen ME; Lloreta J; Babaian RJ
    J Urol; 2005 Dec; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme.
    Scattoni V; Raber M; Capitanio U; Abdollah F; Roscigno M; Angiolilli D; Maccagnano C; Gallina A; Saccà A; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Eur Urol; 2011 Oct; 60(4):834-41. PubMed ID: 21820797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radical Prostatectomy Findings in White Hispanic/Latino Men With NCCN Very Low-risk Prostate Cancer Detected by Template Biopsy.
    Kryvenko ON; Lyapichev K; Chinea FM; Prakash NS; Pollack A; Gonzalgo ML; Punnen S; Jorda M
    Am J Surg Pathol; 2016 Aug; 40(8):1125-32. PubMed ID: 27158756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men.
    Ishimura T; Sakai I; Hara I; Eto H; Miyake H
    Int J Clin Oncol; 2004 Feb; 9(1):47-50. PubMed ID: 15162826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is a sampling transition zone important to increase the detection of prostate cancer in systematic prostatic biopsies?
    Queiroz MR; Falsarella PM; Moreira Valle LG; Cayres Mariotti G; Lemos GC; Alfer Junior W; Garcia RG
    Acta Radiol; 2021 Jun; 62(6):815-820. PubMed ID: 32631078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
    Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
    BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Mariotto A; Brunelli M; Cerruto MA; Cacciamani GE; Migliorini F; Siracusano S; Artibani W
    World J Urol; 2020 Apr; 38(4):957-964. PubMed ID: 31154465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical efficacy of transrectal ultrasound-guided prostate biopsy in men younger than 50 years old with an elevated prostate-specific antigen concentration (>4.0 ng/mL).
    Lu CH; Lin TP; Shen SH; Huang YH; Chung HJ; Kuo JY; Huang WJS; Wu HHH; Chang YH; Lin ATL; Chen KK
    J Chin Med Assoc; 2017 Jul; 80(7):413-418. PubMed ID: 28529023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.
    Jo JK; Lee HS; Lee YI; Lee SE; Hong SK
    Asian J Androl; 2015; 17(2):248-52. PubMed ID: 25432498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy.
    Ficarra V; Novella G; Novara G; Galfano A; Pea M; Martignoni G; Artibani W
    Eur Urol; 2005 Dec; 48(6):932-7. PubMed ID: 16202510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is there any association between National Institute of Health category IV prostatitis and prostate-specific antigen levels in patients with low-risk localized prostate cancer?
    Doluoglu OG; Ceylan C; Kilinc F; Gazel E; Resorlu B; Odabas O
    Int Braz J Urol; 2016; 42(2):346-50. PubMed ID: 27256190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.